Quick Answer
Inhibitor Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $2.38 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -57.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Inhibitor Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 79.7%.
- Historical annual values: Fiscal year 2025: $2.38 million | Fiscal year 2024: $5.61 million | Fiscal year 2023: $8.84 million | Fiscal year 2022: $11.95 million | Fiscal year 2021: $30.6 thousand | Fiscal year 2020: $75.1 thousand | Fiscal year 2019: $803.8 thousand | Fiscal year 2018: $1.11 million | Fiscal year 2017: $344.1 thousand | Fiscal year 2016: $6.89 million | Fiscal year 2015: $601.4 thousand | Fiscal year 2014: $365.2 thousand | Fiscal year 2013: $217.00 | Fiscal year 2012: $857.7 thousand | Fiscal year 2011: $1.32 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: